Compare McDonald's Corp (MCD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs State Street SPDR S&P Biotech ETF — how do they compare? McDonald's Corp trades at $237 (market cap $167.64B), while State Street SPDR S&P Biotech ETF trades at $150.52 (market cap $10.11B). The key difference: McDonald's Corp is far larger — about 16.6× State Street SPDR S&P Biotech ETF's market cap, and McDonald's Corp pays a 3.26% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MCD | XBI | |
|---|---|---|
Market Cap | $167.64B | $10.11B |
Volume | 11,320,306 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $341.06 | $169.55 |
52-Week Low | $230.88 | $104.99 |
Typical Hold Time | 164 Days | 37 Days |
Enterprise Value | $221.41B | — |
Dividend Yield | 3.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $230.88, down 0.68% on the day, with a bearish technical signal from moving averages. The company shows steady revenue growth, reaching $26.89B in 2025, and has consistently beaten EPS estimates in recent quarters. Recent news highlights a new global growth strategy, 'McDonald's NEXT', focusing on automation and improved customer experience to counter competitive pressures and attract diners.
The outlook is mixed: strong fundamentals and a 58.7% analyst buy rating support upside to the $284.70 consensus target, but technical weakness and inflation-driven cost pressures pose near-term risks. The stock offers value through its dividend and defensive profile, yet investors must weigh execution risks of the new strategy against its long-term growth potential.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
